Insulin resistance and coronary heart disease in nondiabetic individuals
Abstract
The goal of this review was to summarize evidence supporting the view that insulin resistance/compensatory hyperinsulinemia play an important role in the pathogenesis of coronary heart disease (CHD) in nondiabetic individuals. Results of case–control and epidemiological studies in nondiabetic individuals will be reviewed to examine the link between insulin resistance/compensatory hyperinsulinemia, associated abnormalities, and CHD. The primary focus of the review will be on the central role that dyslipidemia plays in the link between insulin resistance/compensatory hyperinsulinemia and CHD. Additional issues to be addressed include the following: (1) the relationship among obesity, insulin resistance, and CHD; (2) a listing of other abnormalities that contribute to risk of CHD in insulin-resistant individuals; and (3) discussion of the importance of differential tissue insulin sensitivity in the development of abnormalities that increase CHD risk in insulin-resistant, nondiabetic individuals. The information will reflect the author’s decision as to what issues are believed to be of particular relevance or less well appreciated concerning the complex relationship between insulin resistance and CHD. Resistance to insulin-mediated glucose disposal and hyperinsulinemia is a common finding in apparently healthy individuals and is associated with a number of abnormalities that greatly increase risk of CHD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The same meta-analysis found that pioglitazone reduced future major vascular events (HR 0.75, 95% CI 0.64-0.87; P=.0001) without heterogeneity across clinical trials.
“Another meta-analysis of the risk of recurrent stroke in persons with prior transient ischemic attack or stroke (N 4980 with insulin resistance, prediabetes, or DM) found that pioglitazone reduced the risk of recurrent stroke (HR, 0.68; 95% CI, 0.50–0.92; P = .01) and future major vascular events (HR, 0.75; 95% CI, 0.64–0.87; P = .0001) without heterogeneity across clinical trials (Fig. 5).667”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [667]
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredAnother meta-analysis of recurrent stroke risk in people with prior transient ischemic attack or stroke (N=4980 with insulin resistance, prediabetes, or diabetes) found that pioglitazone reduced the risk of recurrent stroke (HR 0.68, 95% CI 0.50-0.92; P=.01).
“Another meta-analysis of the risk of recurrent stroke in persons with prior transient ischemic attack or stroke (N 4980 with insulin resistance, prediabetes, or DM) found that pioglitazone reduced the risk of recurrent stroke (HR, 0.68; 95% CI, 0.50–0.92; P = .01) and future major vascular events (HR, 0.75; 95% CI, 0.64–0.87; P = .0001) without heterogeneity across clinical trials (Fig. 5).667”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [667]
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 53 · Cited by 227
Research works printed but not linked: 1
- [42]42. Jeng C-Y, Fuh MM-T, Sheu WH-H, Chen Y-DI, Reaven GM. Hormone and substrate modulation of plasma triglyceride concentration in primary hypertriglyceridemia. Endocrinol Metab. 1994;1:15-21.
- Authors
- Reaven, G.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Reaven, Gerald
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2012-08
- Volume
- 32
- Issue
- 8
- Pages
- 1754-1759
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W1980928521
- Cited by
- 227
- References
- 53
- Citations by year
- 2026: 10 · 2025: 18 · 2024: 25 · 2023: 21 · 2022: 16 · 2021: 15 · 2020: 20 · 2019: 14 · 2018: 15 · 2017: 16 · 2016: 15 · 2015: 14 · 2014: 17 · 2013: 9 · 2012: 2
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- insulin resistance, coronary artery disease, compensatory hyperinsulinemia, non-diabetic individuals, dyslipidemia, obesity, insulin sensitivity, cardiovascular risk factors, glucose disposal
- MeSH terms
- Coronary Disease, Diabetes Mellitus, Type 2, Humans, Hyperinsulinism, Insulin Resistance, Cholesterol, HDL, Lipoproteins, LDL, Lipoproteins, VLDL, Obesity, Triglycerides, Postprandial Period
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
